Abstract
In the first six months of its deadly spread across the world, the Covid-19 incidence has exhibited interesting dichotomy between the rich and the poor countries. Surprisingly, the incidence and the Case Fatality Rate has been much higher in the richer countries compared with the poorer countries. However, the reasons behind this dichotomy have not been explained based on data or evidence, although some of the factors for the susceptibility of populations to SARS-CoV-2 infections have been proposed. We have taken into consideration all publicly available data and mined for the possible explanations in order to understand the reasons for this phenomenon. The data included many parameters including demography of nations, prevalence of communicable and non-communicable diseases, sanitation parameters etc. Results of our analyses suggest that demography, improved sanitation and hygiene, and higher incidence of autoimmune disorders as the most plausible factors to explain higher death rates in the richer countries Thus, the much debated “hygiene hypothesis” appears to lend credence to the Case Fatality Rate dichotomy between the rich and the poor countries.
Significance The current COVID-19 epidemic has emerged as one of the deadliest of all infectious diseases in recent times and has affected all nations, especially the developed ones. In such times it is imperative to understand the most significant factor contributing towards higher mortality. Our analysis shows a higher association of demography, sanitation & autoimmunity to COVID-19 mortality as compared to the developmental parameters such as the GDP and the HDI globally. The dependence of sanitation parameters as well as autoimmunity upon the mortality gives direct evidences in support of the lower deaths in nations whose population do not confer to higher standards of hygiene practices and have lower prevalence of autoimmune diseases. This study calls attention to immune training and strengthening through various therapeutic interventions across populations.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
No clinical trials
Funding Statement
BC gratefully acknowledges financial support by the National Centre for Cell Science, Pune. Authors declare no competing financial interests.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No clinical studies performed. Publicly available data was used
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
dataset is available for data.
